Background
==========

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide \[[@b1-medscimonit-22-1742]\]. An estimated total of 989 600 new GC cases and 738 000 deaths occurred in 2008, of which more than 70% occurred in developing countries, with the majority from China \[[@b1-medscimonit-22-1742]\]. GC is a gastrointestinal malignancy caused by environmental and hereditary factors. *Helicobacter pylori* infection and inflammation are important risk factors of GC \[[@b2-medscimonit-22-1742],[@b3-medscimonit-22-1742]\]. IL-1β is an important pro-inflammatory cytokine, mainly produced by inflammatory cells (such as monocytes and macrophages) during the uptake of antigen-antibody complex and antigen presentation, and may expand the inflammatory and immune response \[[@b3-medscimonit-22-1742]\]. In sustained inflammation due to gastric injury, IL-1β may promote COX-2 and iNOS production to inhibit apoptosis and induce cell injury \[[@b4-medscimonit-22-1742]\]. Thus, the IL-1β-related cascade has been proposed as an important mechanism underlying the pathogenesis of GC. Moreover, IL-1β is effective in inhibiting the secretion of gastric acid, with potency 6000 times that of H2 receptor antagonists and 100 times that of proton pump inhibitors \[[@b5-medscimonit-22-1742]\]. The IL-1β-induced inhibition of gastric acid secretion provides a favorable condition for the survival of *H. pylori* in the gastric mucosa and may further cause atrophy of the gastric mucosa \[[@b3-medscimonit-22-1742]\], which creates favorable conditions for malignant transformation of gastric epithelial cells \[[@b6-medscimonit-22-1742]\].

It has been demonstrated that GC susceptibility genes, combined with environmental factors, may play an important role in the development of cancer. In 2000, El-Omar \[[@b7-medscimonit-22-1742]\] first reported that IL-1β gene polymorphism increased the risk of GC onset, a finding subsequently confirmed by later studies \[[@b8-medscimonit-22-1742]--[@b10-medscimonit-22-1742]\]. The IL-1β gene is mapped to chromosome 2q14 and has 3 single-nucleotide polymorphisms (SNPs): 31 T/C, 511 C/T, and 3954 C/T. These 3 SNPs are located in the promoter region of chromosome 2q14 and are thought to cause the overexpression of IL-1β. The correlation between SNP 31T/C and GC has been widely accepted \[[@b11-medscimonit-22-1742],[@b12-medscimonit-22-1742]\], but few studies have investigated SNP 3954 C/T \[[@b13-medscimonit-22-1742],[@b14-medscimonit-22-1742]\]. Thus, this study focusses on the relationship between GC and 511 C/T polymorphism. Xue et al. \[[@b15-medscimonit-22-1742]\] and Park et al. \[[@b16-medscimonit-22-1742]\] have examined the correlation between IL-1β gene polymorphism and GC by meta-analysis, but the population of the studies was worldwide and the language was limited to English. China has the largest population worldwide, but weather this polymorphism increases GC susceptibility in Chinese populations remains controversial and no relevant meta-analyses have been performed. Therefore, we conducted a meta-analysis to examine the correlation between IL-1β-511C/T polymorphism and GC susceptibility in Chinese populations.

Material and Methods
====================

This study was conducted according to the PRISMA statement \[[@b17-medscimonit-22-1742]\].

Inclusion and exclusion criteria
--------------------------------

According to the PICOS principles, the inclusion criteria were: 1) case-control studies in which gene frequency or odds ratio and 95% confidence interval (CI) were included; 2) Chinese patients with pathologically proven GC were recruited; 3) IL-1β-511C/T polymorphism was investigated as an exposure factor; 4) the outcome was onset risk for GC, irrespective of death; and 5) controls were recruited from communities or hospitals and were healthy subjects or volunteers without GC symptoms. Exclusion criteria were: 1) studies in which subjects did not meet the inclusion criteria; 2) subjects whose controls were recruited from gastritis or gastric ulcer patients; 3) subjects whose medical information was incomplete or could not be obtained; and 4) subjects whose language was not Chinese or English.

Literature searching
--------------------

PubMed, EmBase, Cochrane Library, Chinese Biology Medicine, Chinese National Knowledge Infrastructure, and Wanfang databases were searched for studies, published before January 201, on the relationship between IL-1β-511 C/T polymorphism and GC susceptibility in Chinese populations. The search terms were: gastric cancer, gastric carcinoma, polymorphism, variant, mutation, IL-1β, and interleukin-1β. For example, in PubMed the search strategy was: \#1 gastric cancer, \#2 gastric carcinoma, \#3 interleukin-1β, \#4 IL-1β, \#5 polymorphism, \#6 variant, \#7 mutation, \#8 (\#1 OR \#2) AND (\#3 OR \#4) AND (\#5 OR \#6 OR \#7).

Data extraction
---------------

Two investigators independently screened studies and evaluated the study quality. The following information was collected from the studies: first author, publication year, province where the study was conducted, sample size, source of controls, methods for genotyping, *Helicobacter pylori* infection status, genotype frequency including genotype frequency in different types (Lauren's classification) of GC, and *P* value of Hardy-Weinberg equilibrium (HWE). If the *P* value of HWE was not provided, it was calculated with chi square test according to α=0.05. The collected data were double-checked and any discrepancy was resolved by discussion or by contacting the study authors.

Quality evaluation
------------------

The quality of case-control studies was evaluated according to the Newcastle-Ottawa scale (NOS). A total of 8 items are included in the NOS and the maximum score is 9 "stars" \[[@b18-medscimonit-22-1742]\].

Statistical analysis
--------------------

Statistical analysis was performed with STATA 12.0. The overall correlation was evaluated with OR and 95% CI of allele model (T *vs.* C), codominant gene model (TT *vs.* CC; CT *vs.* CC), dominant gene model (TT+CT *vs.* CC), and recessive gene model (TT *vs.* CT+CC).

The I^2^ test was used for test of heterogeneity. If there was mild heterogeneity among studies (*P*≥0.1, *I^2^*\<50%), the fixed-effects model was used; otherwise, the random-effects model was used (*P*\<0.1, *I^2^*≥50%). In addition, subgroup analysis was used to identify the source of heterogeneity on the basis of regions, sources of controls, methods of genotyping, and shift in HWE. In studies in which Lauren's classification of GC was given, subgroup analysis was done according to the intestinal-type and diffuse-type of GC. To avoid the influence of large bias on the overall effectors, stepwise exclusion was employed for the analysis of sensitivity. Funnel plot and Egger's test were used to test for publication bias.

Results
=======

Literature searching
--------------------

The literature search process is shown in [Figure 1](#f1-medscimonit-22-1742){ref-type="fig"}. The initial literature search identified 864 articles. After removal of duplicate articles, 356 articles remained. After the title and abstract of these articles were screened, we excluded the 131 studies unrelated to IL-1β-511C/T polymorphism, 16 reviews or meta-analyses, and 38 studies that were not from Chinese populations. The full text of each of the remaining articles was reviewed, then we excluded studies without data, studies that were not case-control studies, and studies whose control groups included unhealthy subjects. Finally, 28 case-control studies from 27 articles \[[@b19-medscimonit-22-1742]--[@b45-medscimonit-22-1742]\] were included for further analysis.

Characteristics and methodological quality of included studies
--------------------------------------------------------------

The 28 articles were studies conducted with Chinese subjects (including those from Hong Kong, Macao, and Taiwan). Of the 28 studies, 12 were published in English and 16 in Chinese ([Table 1](#t1-medscimonit-22-1742){ref-type="table"}). A total of 5136 GC patients and 5332 healthy controls were included in the 28 studies. China was divided into northern and southern China according to the Qinling-Huaihe line. Patients were recruited from northern China in the 28 studies and from southern China in 14 studies. Population-based (PB) controls were recruited in 13 studies and hospital-based (HB) controls in 15. Lauren's classification was noted in 4 studies. The NOS score of included studies is shown in [Table 1](#t1-medscimonit-22-1742){ref-type="table"}.

Meta-analysis
-------------

Five gene models had obvious heterogeneity; therefore, the random-effects model was used. As shown in [Table 2](#t2-medscimonit-22-1742){ref-type="table"}, the onset risk for GC in mutant T allele carriers was 1.21 times that in non-carriers \[TT *vs.* CC: *OR*=1.41, *95%CI* (1.11--1.80); CT *vs.* CC: *OR*=1.26, *95% CI* (1.05--1.50); TT+CT *vs.* CC: *OR*=1.31, *95%CI* (1.08--1.58); TT *vs.* CT+CC: *OR*=1.24, *95%CI* (1.05--1.47)\]. Each study was omitted in the allele model for sensitivity analysis and the results showed that the effect value ranged from1.07 to 1.37, and 95% CI was 1.04--1.40, suggesting this meta-analysis is statistically robust and reliable.

Subgroup analysis
-----------------

Patients were divided into the southern China group and northern China group. Four gene models proved that IL-1β-511C/T polymorphism increased the susceptibility of GC in patients in southern China. However, no significant correlation between this polymorphism and GC susceptibility was found in patients in northern China in any gene model ([Table 2](#t2-medscimonit-22-1742){ref-type="table"}).

Lauren's classification was mentioned in 4 studies \[[@b30-medscimonit-22-1742],[@b37-medscimonit-22-1742],[@b38-medscimonit-22-1742],[@b44-medscimonit-22-1742]\]. The test for heterogeneity showed little heterogeneity among studies (*I^2^*=0, *P*=0.837), and the fixed-effects model was used. Meta-analysis showed that, in the intestinal-type of GC, the onset risk for GC in mutant T allele carriers was 1.58 times that in non-carriers (*OR*=1.58, *95%CI*: 1.40\~1.79, *P*\<0.01) and consistent results were found in the dominant gene model, co-dominant gene model, and recessive gene model, but in diffuse-type GC, no correlation was observed in any allele model ([Table 2](#t2-medscimonit-22-1742){ref-type="table"}). A forest plot of subgroup meta-analysis according to Lauren's classification in T *vs.* C gene model is shown in [Figure 2](#f2-medscimonit-22-1742){ref-type="fig"}.

Subgroup analysis was also performed according to the source of controls, methods of genotyping, and shift in HWE, and results are shown in [Table 2](#t2-medscimonit-22-1742){ref-type="table"}

Interactions with *H. pylori* infection, IL-1β-31 polymorphism for GC
---------------------------------------------------------------------

Interaction between *H. pylori* infection and IL-1β-511 polymorphism for GC was investigated in 7 studies \[[@b21-medscimonit-22-1742],[@b24-medscimonit-22-1742],[@b27-medscimonit-22-1742],[@b31-medscimonit-22-1742],[@b39-medscimonit-22-1742],[@b42-medscimonit-22-1742],[@b43-medscimonit-22-1742]\]. As in shown in [Table 3](#t3-medscimonit-22-1742){ref-type="table"}, *H. pylori* infection was associated with a trend towards an increased risk of GC, with a pooled OR of 1.9 (*95% CI*: 1.1--3.5, *P*=0.03) in non-carriers of T allele. In subjects not infected with *H. pylori*, the carriage of T (CT+TT) was not associated with an increased susceptibility to GC, with a pooled OR of 1.3 (*95% CI*: 1.0--1.70, *P*=0.75). However, *H. pylori*-infected subjects with carriage of T (CT+TT) exhibited a relatively higher risk of GC, with an OR of 2.4 (*95% CI:* 1.2-5.1, *P*=0.02). These data demonstrate a synergistic interaction between IL-1β-511 and *H. pylori* infection in the occurrence or development of GC.

Within the included studies, the possible interaction between IL-1β-511 and IL-1β-31 polymorphisms in the development of GC was examined only in Zeng's research \[[@b24-medscimonit-22-1742]\], but no linkage disequilibrium was found.

Publication bias
----------------

The Begg's funnel plots of 5 gene models were symmetrical ([Figure 3](#f3-medscimonit-22-1742){ref-type="fig"}). Egger's test also showed no publication bias (Egger value was 0.694, 0.509, 0.426, 0.381, and 0.310 for T *vs.* C, TT *vs.* CC, CT *vs.* CC, TT+CT *vs.* CC, and TT *vs.* CT+CC, respectively) in our research.

Discussion
==========

Since El-Omar first reported that the IL-1β-511 gene allele T carriers was associated with a trend towards an increased onset risk of GC in whites \[[@b7-medscimonit-22-1742]\], several subsequent studies have reported that this association varies among different regions, races, and cultural habits \[[@b31-medscimonit-22-1742],[@b44-medscimonit-22-1742],[@b46-medscimonit-22-1742]\]. The relationship between IL-1β 511C/T polymorphisms and GC susceptibility in Chinese populations had been investigated in numerous case-control studies, but conflicting results were reported \[[@b36-medscimonit-22-1742]\].We conducted a meta-analysis to investigate this possible correlation in Chinese populations by using 5 gene models. A total of 28 case-control studies were recruited from 27 relevant studies, and this meta-analysis showed that IL-1β 511C/T polymorphism significantly increased GC susceptibility in Chinese subjects, a finding which is consistent with those of Yu \[[@b38-medscimonit-22-1742]\] and Zhao \[[@b44-medscimonit-22-1742]\]. Subgroup analysis showed that IL-1β 511C/T polymorphism increased the onset risk for GC in Chinese subjects in southern China, but not in northern China. According to Lauren's classification, IL-1β 511C/T polymorphism increased the onset risk for intestinal-type GC, but not for diffuse-type GC.

The incidence of GC was influenced by regional differences. East Asians have relatively higher morbidity of GC, especially in China, Japan, and Korea, accounting for 60% of GC cases worldwide \[[@b47-medscimonit-22-1742]\]. The number of GC cases in China accounted for 40% in these 3 countries, although the incidence is lower than in Japan and Korea. Epidemiological statistics also showed the incidence of GC was not entirely consistent in different regions \[[@b48-medscimonit-22-1742]\]. The Qinling-Huaihe line is the geographical boundary between northern and southern China, with differences in hereditary background, climate, and diet and other lifestyle factors \[[@b49-medscimonit-22-1742]\]. In this study, we investigated the association between IL-1β-511C/T polymorphism and onset risk for GC in Chinese subjects in southern and northern China. Our results showed that IL-1β-511C/T polymorphism significantly increased GC susceptibility of Chinese in southern China, but not in northern China. This finding implies that the hereditary background is different between GC patients in these 2 regions.

In 1965, Lauren classified GC into the intestinal type and diffuse type according to the pathological features \[[@b50-medscimonit-22-1742]\]. This analysis showed that IL-1β-511C/T polymorphism significantly increased the onset risk for intestinal-type GC, but had no influence on the onset risk of diffuse-type GC. Intestinal-type GC was generally accompanied by high or moderate differentiation and has a relatively good prognosis, but diffuse-type GC was the opposite \[[@b51-medscimonit-22-1742]\]. The IL-1β-511C/T gene was correlated with occurrence of intestinal-type GC, but determining whether detection of its mutation would help to assess the prognosis of GC needs epidemiological studies.

The potential mechanisms of tumorigenesis are inexplicable as a result of the involvement of multiple risk factors, including the complicated gene-environment and gene-gene interactions \[[@b52-medscimonit-22-1742]\]. *H. pylori* infection is regarded as the major cause of GC among environmental factors \[[@b2-medscimonit-22-1742]\]. In this meta-analysis, we found the susceptibility to GC was significantly increased for T carriers of IL-1β-511C/T polymorphism with *H. pylori* infection, suggesting that a synergistic interaction between IL-1β-511 and *H. pylori* infection exists in the development of GC, which is consistent with results reported by Li \[[@b31-medscimonit-22-1742]\].

Gastric epithelial cells were damaged by inflammation and immune response induced by vacuole toxin and ammonia generated by *H. pylori.* As a pro-inflammatory factor produced in response to various stimuli, IL-1β plays an important role in the promotion of inflammatory response and expansion of immune responses. Moreover, the overexpression of IL-1β can inhibit gastric acid secretion, thus providing a more favorable environment for the survival and growth of *H. pylori*, which could further cause atrophy and damage of the gastric mucosa \[[@b6-medscimonit-22-1742]\]. There 2 mechanisms may explain the conclusion that IL-1β-511C/T polymorphism and its expression contribute to host susceptibility to GC in subjects with *H. pylori* infection.

Cox first reported the linkage disequilibrium in the interleukin-1 gene cluster and synergistic effects between IL-1β-511 and IL-1β-31polymorphism in 212 white subjects \[[@b53-medscimonit-22-1742]\]. However, in Zeng's study \[[@b24-medscimonit-22-1742]\] no evidence of linkage disequilibrium was found between the 2 SNPs in both high prevalence and low prevalence regions, suggesting that the 2 SNPs were independent risk factors for GC in both areas.

We acknowledge that our study has limitations. 1) The sample size of studies included was not large. 2) Some models have considerable heterogeneity. 3) There were differences in patients and controls among studies, and the sources of controls were inconsistent among studies; in several studies, some controls were recruited from hospitals but others from the general population, thus introducing the possibility of selection bias. 4) Only 4 studies stratified patients according to Lauren's classification, and subgroup analysis for pathological types other than intestinal-type GC and diffuse-type GC could not be conducted. Because of these factors, the universality of our conclusions is limited. Multicenter, randomized, controlled studies with larger sample sizes are needed to confirm the relationship between IL-1β-511C/T polymorphism and GC susceptibility. Confirmation of this relationship may provide new ideas and clues for the prevention and therapy of GC and accelerate realization of its clinical value.

Conclusions
===========

This meta-analysis indicated that IL-1β-511C/T polymorphism was significantly associated with increased susceptibility to GC in Chinese populations, mainly in residents of southern China and in intestinal-type GC. We found a synergistic interaction between IL-1β-511C/T polymorphism and *H. pylori* infection in the development of GC. However, further studies are needed to clarify the specific mechanism of the IL-1β-511C/T polymorphisms in the etiology of gastric cancer.
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###### 

Characteristics and quality of included studies.

  Studies                                      Province            Source of controls   Genotyping     Sample (patients/ controls)   Genotype      HWE value    NOS score   Lauren type   *H. pylori* infection   
  -------------------------------------------- ------------------- -------------------- -------------- ----------------------------- ------------- ------------ ----------- ------------- ----------------------- -----
  He, 2002 \[[@b19-medscimonit-22-1742]\]      Liaoning            HB                   PCR-RFLP       50/50                         15/23/12      28/19/3      0.92        5             No                      No
  Wu, 2003 \[[@b20-medscimonit-22-1742]\]      Taiwan              HB                   PCR-RFLP       220/230                       69/106/45     61/124/45    0.21        7             No                      No
  Chen, 2004 \[[@b21-medscimonit-22-1742]\]    Taiwan              HB                   PCR-RFLP       142/164                       24/87/31      34/93/37     0.65        7             No                      Yes
  Yang, 2004 \[[@b22-medscimonit-22-1742]\]    Jiangsu             PB                   PCR-RFLP       280/258                       70/158/52     57/136/65    0.37        7             No                      No
  Hu, 2004 \[[@b23-medscimonit-22-1742]\]      Shanxi              PB                   PCR-RFLP       169/86                        34/97/38      19/45/22     0.66        7             No                      No
  Zeng, 2005 \[[@b24-medscimonit-22-1742]\]    Shanxi              HB                   PCR-RFLP       102/102                       28/46/28      25/52/25     0.42        6             No                      Yes
  Zeng, 2005 \[[@b24-medscimonit-22-1742]\]    Guangdong           HB                   PCR-RFLP       104/104                       24/52/28      32/58/14     0.13        6             No                      Yes
  Lu, 2005 \[[@b25-medscimonit-22-1742]\]      Beijing, Shandong   PB                   DH. PYLORILC   250/300                       72/125/53     67/163/70    0.13        7             No                      No
  Zhang, 2005 \[[@b26-medscimonit-22-1742]\]   Gansu               PB                   PCR-RFLP       154/166                       34/78/42      43/71/52     0.07        6             No                      No
  Xing, 2006 \[[@b27-medscimonit-22-1742]\]    Shandong            HB                   Taq            130/142                       57/33/40      68/46/28     \<0.05      6             No                      Yes
  Gao, 2006 \[[@b28-medscimonit-22-1742]\]     Shandong            HB                   PCR-RFLP       71/65                         25/23/23      39/12/14     \<0.05      5             No                      No
  Zheng, 2007 \[[@b29-medscimonit-22-1742]\]   Shanghai            HB                   PCR-RFLP       177/298                       49/83/45      77/140/81    0.3         7             No                      No
  Wei, 2007 \[[@b30-medscimonit-22-1742]\]     Henan               PB                   PCR-SSCP       452/218                       112/290/50    100/87/31    0.1         5             yes                     No
  Li, 2007 \[[@b31-medscimonit-22-1742]\]      Hubei               HB                   PCR-RFLP       143/264                       29/75/39      70/137/57    0.51        6             No                      Yes
  Zhang, 2007 \[[@b32-medscimonit-22-1742]\]   Shandong            PB                   PCR-RFLP       214/230                       55/97/62      56/101/73    0.08        7             No                      No
  Sun, 2007 \[[@b33-medscimonit-22-1742]\]     Shandong            HB                   Oligochip      65/55                         39/12/14      25/13/17     \<0.05      6             No                      No
  Feng, 2008 \[[@b34-medscimonit-22-1742]\]    Henan               PB                   PCR-RFLP       150/154                       42/54/54      91/33/30     \<0.05      7             No                      No
  Jia, 2009 \[[@b35-medscimonit-22-1742]\]     Shanxi              HB                   PCR-RFLP       106/108                       13/58/35      18/55/35     0.65        7             No                      No
  Xiang, 2009 \[[@b36-medscimonit-22-1742]\]   Chongqing           HB                   PCR-RFLP       35/70                         9/15/2011     18/27/25     0.06        6             No                      No
  Chen, 2009 \[[@b37-medscimonit-22-1742]\]    Guangdong           PB                   PCR-RFLP       563/500                       143/309/111   182/253/65   0.11        6             Yes                     No
  Yu, 2009 \[[@b38-medscimonit-22-1742]\]      Guangdong           PB                   PCR-RFLP       501/500                       132/269/100   182/253/65   0.7         7             Yes                     No
  Jiang, 2010 \[[@b39-medscimonit-22-1742]\]   Hubei               PB                   PCR-RFLP       84/84                         19/44/21      37/38/9      0.87        7             No                      Yes
  Li, 2010 \[[@b40-medscimonit-22-1742]\]      Sichuan             PB                   PCR-RFLP       140/165                       26/81/33      34/94/37     0.07        7             No                      No
  Zou, 2011 \[[@b41-medscimonit-22-1742]\]     Guangdong           HB                   MALDI-TOFM     52/52                         20/23/9       11/28/2013   0.57        6             No                      No
  He, 2011 \[[@b42-medscimonit-22-1742]\]      Jiangsu             HB                   PCR-RFLP       392/508                       72/196/124    148/266/94   0.18        7             No                      Yes
  Zhang, 2012 \[[@b43-medscimonit-22-1742]\]   Jiangsu             HB                   PCR-RFLP       128/127                       28/61/39      37/71/19     0.11        6             No                      Yes
  Zhao, 2012 \[[@b44-medscimonit-22-1742]\]    Qinghai             PB                   PCR-RFLP       197/202                       31/101/65     65/99/38     0.98        7             Yes                     No
  Zhang, 2014 \[[@b45-medscimonit-22-1742]\]   Henan               PB                   PCR-RFLP       65/130                        12/34/19      10/76/44     \<0.05      7             No                      No

HB -- hospital-based; PB -- population-based; PCR-RFLP -- restriction fragment length polymorphism polymerase chain reaction; DHPLC -- denaturing high performance liquid chromatography; Taq -- Taq polymerase chain reaction; MALDI-TOFMS -- matrix-assisted laser desorption ionization time of flight mass spectrometry.

###### 

Results of meta-analysis for the IL-1β-511C/T polymorphism and GC risk.

  Subgroup             Studies   T *vs.* C           TT *vs.* CC   CT *vs.* CC   (TT+CT) *vs.* CC     TT *vs.* (CC+CT)                                                                                                             
  -------------------- --------- ------------------- ------------- ------------- -------------------- ------------------ ------ -------------------- ------- ------ ------------------- ------- ------ ------------------- ------- ------
  Total                28        1.21 (1.07--1.37)   0.003         78.7          1.41 (1.11--1.80)    0.005              75.1   1.26 (1.05--1.50)    0.013   68.8   1.31 (1.08--1.58)   0.005   75.3   1.24 (1.05--1.47)   0.013   65.6
  Region               28                                                                                                                                                                                                          
  North                13        1.27 (0.99--1.55)   0.060         82.7          1.42 (0.93--.170)    0.103              77.1   1.25 (0.88--1.74)    0.161   72.1   1.32 (0.94--1.84)   0.107   80     1.22 (0.83--2.20)   0.118   58.1
  South                15        1.58 (1.11--2.24)   0.015         74.5          1.45 (1.07--2.00)    0.016              73     1.28 (1.03--1.59)    0.029   66.0   1.32 (1.05--1.65)   0.016   71.4   1.26 (0.99--1.60)   0.062   69.4
  Source of controls   28                                                                                                                                                                                                          
  Population based     13        1.31 (1.07--1.60)   0.008         84.7          1.57 (1.06--2.32)    0.023              82     1.48 (1.12--1.97)    0.006   77.9   1.52 (1.13--2.05)   0.005   82.3   1.24 (0.99--1.55)   0.108   73.7
  Hospital based       15        1.13 (0.96--1.32)   0.132         69.2          1.38 (1.02--1.86)    0.084              67.6   1.09 (0.94--1.26)    0.245   32.4   1.14 (0.92--1.41)   0.234   59.9   1.28 (1.03--1.60)   0.054   57.1
  Genotyping           28                                                                                                                                                                                                          
  PCR-RFLP             24        1.24 (1.08--1.42)   0.002         78.6          1.56 (1.20--2.02)    0.002              75.4   1.32 (1.19--1.46)    0       54.6   1.35 (1.12--1.63)   0.002   70.5   1.29 (1.08--1.55)   0.006   65.6
  Other                4         1.04 (0.72--1.51)   0.819         81.8          1.00 (0.57--1.75 )   0.992              68.8   1.30 (1.04--1.64)    0.024   91.6   1.03 (0.49--2.19)   0.934   90.4   0.97 (0.63--1.47)   0.871   56.6
  HWE                  28                                                                                                                                                                                                          
  Yes                  23        1.19 (1.05--1.34)   0.005         74.6          1.41 (1.10--1.81)    0.006              73.3   1.26 (1.06--1.50)    0.009   62.8   1.30 (1.08--1.58)   0.004   74.3   1.22 (1.07--1.46)   0.037   66.6
  No                   5         1.30 (0.74--2.27)   0.366         89.1          1.33 (0.58--3.08)    0.502              84.1   1.185 (0.50--2.81)   0.700   85.3   1.25 (0.55--2.82)   0.594   34.1   1.35 (0.83--2.20)   0.226   64.8
  Lauen type           4                                                                                                                                                                                                           
  Intestinal           4         1.58 (1.40--1.79)   0.00          0             2.71 (2.08--3.52)    0                  0      1.81 (1.29--2.53)    0.001   62     1.96 (1.51--2.54)   0       42     1.83 (1.39--2.41)   0       21.1
  Diffuse              4         1.09 (0.9--1.32)    0.374         27.9          0.95 (0.44--2.02)    0.883              61.1   1.02 (0.86--1.54)    0.231   56.2   1.43 (0.74--1.60)   0.428   62     0.73 (0.35--1.52)   0.395   67

###### 

Combined risks of IL-1β-511 polymorphism and *H. pylori* infection for GC.

  IL-1β-511 polymorphism   *H. pylori* infection   OR (95% CI)      P value
  ------------------------ ----------------------- ---------------- ---------
  C homozygote             (−)                     1                --
  T carrier                (−)                     1.3 (1.0--1.7)   0.75
  C homozygote             (+)                     1.9 (1.1--3.5)   0.03
  T carrier                (+)                     2.4 (1.2--5.1)   0.02
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